Arcellx Inc (ACLX, Financial), a clinical-stage biopharmaceutical company focusing on the development of novel cell-based cancer therapies, has reported an insider sell according to the latest SEC filings. The company's Chief Medical Officer, Christopher Heery, sold 46,815 shares of the company on March 26, 2024. The transaction was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC Filing).
Over the past year, the insider has sold a total of 242,063 shares of Arcellx Inc (ACLX, Financial) and has not made any purchases of the stock. This latest transaction continues a trend of insider sells at the company, with a total of 24 insider sells and no insider buys reported over the past year.
On the date of the reported sell, shares of Arcellx Inc (ACLX, Financial) were trading at $70.06 each, valuing the company at a market cap of $3.702 billion.
The insider transaction history for Arcellx Inc (ACLX, Financial) suggests a pattern of insider sales over the past year, which can be visualized in the following insider trend image:
Investors often monitor insider transactions as part of their due diligence process, as these transactions can provide insights into the perspectives of those with in-depth knowledge of the company. However, it is important to consider a wide range of factors when evaluating the potential implications of insider trading activity.
For more detailed information on insider transactions and the financial performance of Arcellx Inc (ACLX, Financial), interested parties are encouraged to review the company's filings with the SEC and other publicly available financial data.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
